## Forest plots for review question: What is the effectiveness of uterotonics for the prevention of postpartum haemorrhage?

This section includes forest plots only for outcomes that are meta-analysed, but were not included in the NMA. Outcomes from single studies are not presented here; the quality assessment for such outcomes is provided in the GRADE profiles in appendix F.

## Postpartum haemorrhage ≥ 1000 mL

Figure 31: Ergometrine versus Misoprostol ≤600mcg – Vaginal birth

	Ergome	trine	Misoprosto	I 600		Risk Difference	Risk Difference	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Chhabra 2008	0	100	0	200	26.8%	0.00 [-0.02, 0.02]	•	
Humera 2016	0	50	0	50	10.0%	0.00 [-0.04, 0.04]	†	
Jago 2007	0	254	0	256	51.2%	0.00 [-0.01, 0.01]	•	
Vimala 2004	0	60	0	60	12.0%	0.00 [-0.03, 0.03]	†	
Total (95% CI)		464		566	100.0%	0.00 [-0.01, 0.01]	ı (	
Total events	0		0					
Heterogeneity: Chi²=	0.00, df=	3(P = 1)	$.00$ ); $I^{z} = 0\%$				-1 -0.5 0 0.5	<del> </del>
Test for overall effect:	Z = 0.00 (	P = 1.00	0)				Favours Ergometrine Favours Miso 600	'

Figure 32: Misoprostol ≤600mcg versus Oxytocin >5 iu to ≤ 10 iu – Vaginal birth

	Misoprosto	1600	Oxytocin	5-10		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Afolabi 2010	0	100	0	100	5.0%	0.00 [-0.02, 0.02]	+
Bellad 2012	0	321	0	331	16.4%	0.00 [-0.01, 0.01]	•
Bhatti 2014	0	60	0	60	3.0%	0.00 [-0.03, 0.03]	+
Gupta 2006	0	100	0	100	5.0%	0.00 [-0.02, 0.02]	†
Oboro 2003	0	247	0	249	12.5%	0.00 [-0.01, 0.01]	•
Sadiq 2011	0	900	0	900	45.4%	0.00 [-0.00, 0.00]	•
Tewatia 2014	0	50	0	50	2.5%	0.00 [-0.04, 0.04]	+
Walley 2000	0	202	0	196	10.0%	0.00 [-0.01, 0.01]	†
Total (95% CI)		1980		1986	100.0%	0.00 [-0.00, 0.00]	
Total events	0		0				
Heterogeneity: Chi²=	, ,		); l² = 0%				-1 -0.5 0 0.5 1
Test for overall effect:	Z = 0.00 (P =	1.00)					Favours Miso 600 Favours Oxytocin 5-10

Figure 33:	Oxytoo	in >	1 iu t	o ≤ 5	iu ve	ersus Carbe	tocin
	Oxytocin	1-5	Carbete	ocin		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
12.1.1 Vaginal Birth							
Amornpetchakul 2018 Subtotal (95% CI)	0	174 <b>174</b>	0	176 <b>176</b>	87.3% <b>87.3</b> %	0.00 [-0.01, 0.01] <b>0.00 [-0.01, 0.01]</b>	<del>-</del>
Total events	0		0				
Heterogeneity: Not app	olicable						
Test for overall effect: 2	Z = 0.00 (P =	1.00)					
12.1.2 Caesarean Birt	h						
Rosseland 2013	0	26	0	25	12.7%	0.00 [-0.07, 0.07]	+
Subtotal (95% CI)		26		25	12.7%	0.00 [-0.07, 0.07]	•
Total events	0		0				
Heterogeneity: Not app	olicable						
Test for overall effect: 2	Z = 0.00 (P =	1.00)					
Total (95% CI)		200		201	100.0%	0.00 [-0.01, 0.01]	•
Total events	0		0				
Heterogeneity: Chi² = 0	0.00, df = 1 (F	P = 1.00	)); I² = 0%				-1 -0.5 0 0.5 1
Test for overall effect: 2	Z = 0.00 (P =	1.00)					Favours Oxytocin 1 - 5 Favours Carbetocin
Test for subgroup diffe	rences: Chi <sup>a</sup>	= 0.00	, df = 1 (P	= 1.003	, I² = 0%		ravours oxytostii i o ravours ourbetotiii

Figure 34:	_		1 iu t	:o ≤	5 iu v	ersus Placel		
	Oxytocir	11-5	Place	bo		Risk Difference	Risk Difference	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
13.1.1 Vaginal Birth								
Jerbi 2007	0	65	0	65	71.8%	0.00 [-0.03, 0.03]		
Subtotal (95% CI)		65		65	71.8%	0.00 [-0.03, 0.03]		
Total events	0		0					
Heterogeneity: Not as	oplicable							
Test for overall effect:	Z = 0.00 (F	P = 1.00)	)					
13.1.2 Caesarean Bi	rth							
Rosseland 2013	0	26	0	25	28.2%	0.00 [-0.07, 0.07]	<del>-</del>	
Subtotal (95% CI)		26		25	28.2%	0.00 [-0.07, 0.07]	<b>◆</b>	
Total events	0		0					
Heterogeneity: Not ap	oplicable							
Test for overall effect:	Z = 0.00 (F	P = 1.00)	)					
Total (95% CI)		91		90	100.0%	0.00 [-0.03, 0.03]	•	
Total events	0		0					
Heterogeneity: Chi <sup>z</sup> =	0.00, df=	1 (P = 1.	$(00); I^2 = 0$	0%			-1 -0.5 0 0.5	<u> </u>
Test for overall effect:	Z = 0.00 (F	e = 1.00)	)				-1 -0.5 0 0.5 Favours Oxytocin 1 - 5 Favours Placebo	1
Test for subgroup dif	ferences: C	hi² = 0.i	00, df = 1	(P = 1.	00), $I^2 = 0$	1%	ravours Oxylociii i - 5 Favours Placebo	

## Severe maternal morbidity – intensive care admissions

Figure 35: Misoprostol >600 mcg to ≤800 mcg versus Oxytocin >1 iu to ≤ 5 iu – Vaginal birth

	Misoprostol 600 t	to 800	Oxytocin '	1 to 5		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Amin 2014	0	100	0	100	28.0%	0.00 [-0.02, 0.02]	•
Nasr 2009	0	257	0	257	72.0%	0.00 [-0.01, 0.01]	•
Total (95% CI)		357		357	100.0%	0.00 [-0.01, 0.01]	
Total events	0		0				
Heterogeneity: Chi²=	0.00, $df = 1$ ( $P = 1.0$	00); I² = 0	%				-1 -0.5 0 0.5 1
Test for overall effect:	Z = 0.00 (P = 1.00)						Favours Miso 600 to 800 Favours Oxy 1 to 5

Figure 36: Misoprostol ≤600 mcg versus Oxytocin >5 iu to ≤ 10 iu – Vaginal birth

	Misoprosto	ol 600	Oxytocin 5	to 10		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Afolabi 2010	0	100	0	100	20.0%	0.00 [-0.02, 0.02]	•
Kundodyiwa 2001	0	243	0	256	49.9%	0.00 [-0.01, 0.01]	•
Musa 2015	0	100	0	100	20.0%	0.00 [-0.02, 0.02]	<b>+</b>
Tewatia 2014	0	50	0	50	10.0%	0.00 [-0.04, 0.04]	†
Total (95% CI)		493		506	100.0%	0.00 [-0.01, 0.01]	
Total events	0		0				
Heterogeneity: Chi <sup>2</sup> =	= 0.00, df = 3 (	P = 1.00	)); I² = 0%				-1 -0.5 0 0.5 1
Test for overall effect	:: Z = 0.00 (P =	1.00)					Favours Misoprostol 600 Favours Oxytocin 5 to 10

Figure 37: Ergometrine + Oxytocin versus Carbetocin – Vaginal birth

	Ergometrine + Oxytocin		Carbeto	ocin		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Nirmala 2009	0	60	0	60	37.5%	0.00 [-0.03, 0.03]	•
Samimi 2013	0	100	0	100	62.5%	0.00 [-0.02, 0.02]	•
Total (95% CI)		160		160	100.0%	0.00 [-0.02, 0.02]	•
Total events	0		0				
Heterogeneity: Chi² = Test for overall effect:	, ,	); I² = 09	%				-1 -0.5 0 0.5 1 Favours Ergo+Oxy Favours Carbetocin

## **Need for blood transfusion**

Figure 38: Ergometrine versus Misoprostol ≤600 mcg – Vaginal birth

	Ergome	trine	Misoprostol	<600		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Chhabra 2008	0	100	0	200	33.9%	0.00 [-0.02, 0.02]	•
Humera 2016	0	50	0	50	12.7%	0.00 [-0.04, 0.04]	+
Otoide 2020	0	150	0	150	38.1%	0.00 [-0.01, 0.01]	•
Vimala 2004	0	60	0	60	15.3%	0.00 [-0.03, 0.03]	†
Total (95% CI)		360		460	100.0%	0.00 [-0.01, 0.01]	
Total events	0		0				
Heterogeneity: Chi²=	0.00, df=	3(P = 1)	$.00$ ); $I^2 = 0\%$				-1 -0.5 0 0.5 1
Test for overall effect:	Z = 0.00 (	P = 1.00	))				Favours Ergometrine Favours Miso 600

Figure 39: Misoprostol ≤600 mcg versus Ergometrine + Oxytocin – Vaginal birth

	Misoprosto	<600	Ergometrine + O:	xytocin		Risk Difference		Risk Di	iffere	nce	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ed, 95	5% CI	
Bamigboye, Merrell 1998	0	231	0	233	76.8%	0.00 [-0.01, 0.01]					
Harriott 2009	0	70	0	70	23.2%	0.00 [-0.03, 0.03]			<b>†</b>		
Total (95% CI)		301		303	100.0%	0.00 [-0.01, 0.01]					
Total events	0		0								
Heterogeneity: Chi <sup>2</sup> = 0.00,	df = 1 (P = 1.0)	$ 0\rangle;  ^2 = 0$	%				1	-0.5	+	0.5	<u> </u>
Test for overall effect: Z = 0	.00 (P = 1.00)						-1	Favours Miso 600	Fav		'

Figure 40:	Misopro	stol	≤600 r	ncg v	ersu:	s Oxytocin >	>5 iu to ≤ 10 iu
•	Misoprostol	<600	Oxytocin	5-10		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
11.1.1 Vaginal birth							
Afolabi 2010	0	100	0	100	5.9%	0.00 [-0.02, 0.02]	+
Gupta 2006	0	100	0	100	5.9%	0.00 [-0.02, 0.02]	+
Lumbiganon 1999	0	397	0	200	15.6%	0.00 [-0.01, 0.01]	•
Oboro 2003	0	247	0	249	14.5%	0.00 [-0.01, 0.01]	•
Sadiq 2011	0	900	0	884	52.3%	0.00 [-0.00, 0.00]	•
Tewatia 2014 Subtotal (95% CI)	0	50 <b>1794</b>	0	50 <b>1583</b>	2.9% <b>97.1</b> %	0.00 [-0.04, 0.04] <b>0.00 [-0.00, 0.00]</b>	†
Total events	n		Ω		011170	0.00 [ 0.00, 0.00]	
Heterogeneity: Chi <sup>2</sup> =	_	= 1.00\	_				
Test for overall effect			. 0%				
11.1.2 Caesarean bii	rth						
Fazel 2013	0	50	0	50	2.9%	0.00 [-0.04, 0.04]	<u>†</u>
Subtotal (95% CI)	_	50		50	2.9%	0.00 [-0.04, 0.04]	<b>T</b>
Total events	0		0				
Heterogeneity: Not ap							
Test for overall effect	Z = 0.00 (P = 1	.00)					
Total (95% CI)		1844		1633	100.0%	0.00 [-0.00, 0.00]	(
Total events	0		0				
Heterogeneity: Chi²=	0.00, df = 6 (P	= 1.00);	$I^2 = 0\%$				-1 -0.5 0 0.5 1
Test for overall effect	Z = 0.00 (P = 1)	.00)					Favours Miso 600 Favours Oxytocin 5-10
Test for subgroup dif	ferences: Chi²=	= 0.00, 0	df = 1 (P =	1.00), I²	= 0%		Tarout S initio 500 Tarout S Oxytochi 5-10

Figure 41:	Misopro	stol:	≤600 n	ncg	versu	s Oxytocin >	>1 iu to ≤ 5 iu – Vaginal birth
	Misoprostol	<600	Oxytocii	า 1-5		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	I M-H, Fixed, 95% CI
Baskett 2007	0	311	0	311	73.6%	0.00 [-0.01, 0.01]	]
Karkanis 2002	0	110	0	113	26.4%	0.00 [-0.02, 0.02]	J †
Total (95% CI)		421		424	100.0%	0.00 [-0.01, 0.01]	1
Total events	0		0				
Heterogeneity: Chi² =			; I² = 0%				-1 -0.5 0 0.5 1
Test for overall effect	E Z = 0.00 (P = 1)	1.00)					Favours Miso 600 Favours Oxytocin 1-5




Figure 43: Oxytocin >5 iu to ≤ 10 iu versus Carbetocin Oxytocin 5-10 Carbetocin Risk Difference Risk Difference Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI 17.1.1 Vaginal birth 30 37.5% 0.00 [-0.06, 0.06] 30 37.5% 0.00 [-0.06, 0.06] Fenix 2012 30 Subtotal (95% CI) 30 0 Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.00 (P = 1.00) 17.1.2 Caesarean birth 50 62.5% 0.00 [-0.04, 0.04] Fahmy 2015 50 Subtotal (95% CI) 50 50 62.5% 0.00 [-0.04, 0.04] Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.00 (P = 1.00) Total (95% CI) 80 80 100.0% 0.00 [-0.03, 0.03] Total events 0 Heterogeneity:  $Chi^2 = 0.00$ , df = 1 (P = 1.00);  $I^2 = 0\%$ -0.5 0.5 Test for overall effect: Z = 0.00 (P = 1.00) Favours Oxytocin 5-10 Favours Carbetocin Test for subgroup differences:  $Chi^2 = 0.00$ , df = 1 (P = 1.00),  $I^2 = 0\%$ 

